Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cirtuvivint as Monotherapy and in Combination With ASTX727 in MDS and AML
NCT06484062Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cirtuvivint in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 3 years. Started Aug 2025; status: recruiting.
02
Drugs
cirtuvivint
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06484062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484062.